AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 4 - (NewsRx.com & NewsRx.net) -- Neurologists in Japan report enhancement of antitumor immune responses in murine models of brain tumors by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.
R. Yamanaka and colleagues at Niigata University conducted a study of dendritic cell (DC)-based immunotherapy for malignant brain tumor to improve the therapeutic efficacy of this treatment strategy.
"Dendritic cells were isolated from bone marrow and pulsed with phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector GCsap-interleukin (IL)-12, and SFV-IL-12, respectively, to treat mice bearing brain tumors of the B16 cell line," they said.
The researchers said their "results indicated that therapeutic immunization with DCs pulsed with SFV-IL-12 prolonged the survival of mice with established tumors. Semliki Forest virus induced apoptosis in DCs, which in turn facilitated the uptake of apoptotic cells by other DCs, thus providing a potential mechanism for enhanced immunogenicity," stated Yamanaka and colleagues.
They concluded: "Therapy with DCs that have been pulsed with SFV-mediated IL-12 may ...
Source: HighBeam Research, Dendritic-cell based immunotherapy may have potential against brain...